Related Experiment Video

Updated: Oct 21, 2025

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.5K

Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins

Mathilde Letzelter1, Xavier Grimaux

  • 1Mathilde Letzelter, MD, 4 Rue Larrey, 49100 Angers, mathilde.letzelter@hotmail.fr.

Acta Dermatovenerologica Croatica : ADC
|September 3, 2021
PubMed

Insights

Scleromyxedema, a rare skin condition, can be effectively treated with intravenous immunoglobulins, even in cases without associated monoclonal gammopathy. This treatment offers a potential therapeutic option for managing this unpredictable disease.

Area of Science:

  • Dermatology
  • Immunology
  • Internal Medicine

Background:

  • Scleromyxedema is a rare generalized cutaneous mucinosis often linked to monoclonal gammopathy.
  • The physiopathological mechanisms and natural course of scleromyxedema remain incompletely understood.
  • Potential for fatal complications necessitates effective treatment strategies.

Observation:

  • A case of scleromyxedema was observed.
  • This patient did not present with associated monoclonal gammopathy.
  • The patient received monthly courses of intravenous immunoglobulins.

Findings:

  • Intravenous immunoglobulins demonstrated effectiveness in treating scleromyxedema.
  • The treatment was successful despite the absence of monoclonal gammopathy.
  • Monthly administration of intravenous immunoglobulins proved beneficial.

Implications:

  • Intravenous immunoglobulins represent a viable treatment for scleromyxedema, irrespective of monoclonal gammopathy status.
  • This finding expands treatment options for scleromyxedema patients.
  • Further research is warranted to elucidate the interaction between intravenous immunoglobulins and scleromyxedema pathophysiology.

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.4K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.7K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
289
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
241
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
261